Miwa, Kunihisa · Internal medicine (Tokyo, Japan) · 2021 · DOI
Researchers tested whether minocycline, an antibiotic that may reduce brain inflammation, could help ME/CFS patients. About 27% of 100 patients taking minocycline for 6 weeks experienced meaningful symptom improvement, particularly those who had been sick for less than 3 years. However, 38% of patients had to stop taking it early due to side effects like nausea and dizziness.
This is among the first clinical explorations of minocycline's neuroprotective properties in ME/CFS patients, offering a potential therapeutic avenue targeting neuroinflammation. The finding that early-stage patients respond better suggests a time-sensitive window for intervention, which could inform treatment timing strategies. If validated in controlled trials, this could provide patients—especially those newly diagnosed—with an additional evidence-based treatment option.
This study does not prove minocycline is an effective ME/CFS treatment; it is observational without a placebo or control group, so symptom improvements could reflect natural variation, placebo response, or other factors. The high discontinuation rate (38%) and modest response rate (27%) mean the drug's actual clinical utility remains unclear. This finding does not establish that neural inflammation is the cause of ME/CFS, only that minocycline may benefit some patients, particularly early in disease.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Miwa, Kunihisa (2021). Oral Minocycline Therapy Improves Symptoms of Myalgic Encephalomyelitis, Especially in the Initial Disease Stage.. Internal medicine (Tokyo, Japan). https://doi.org/10.2169/internalmedicine.6082-20
BibTeX
@article{mecfsatlas-miwa-2021-oral-minocycline,
author = {Miwa, Kunihisa},
title = {Oral Minocycline Therapy Improves Symptoms of Myalgic Encephalomyelitis, Especially in the Initial Disease Stage.},
journal = {Internal medicine (Tokyo, Japan)},
year = {2021},
doi = {10.2169/internalmedicine.6082-20},
note = {PubMed: 33896862},
url = {https://www.mecfsatlas.com/evidence/miwa-2021-oral-minocycline},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-05-30. https://www.mecfsatlas.com/evidence/miwa-2021-oral-minocycline
Contribute
Private, reviewed by a human. Not a public comment thread.